Tenofovir Disoproxil Fumarate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Tenofovir Disoproxil Fumarate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
402
Registered trials
184
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Tenofovir Disoproxil Fumarate can convert its Small molecule drug profile and DNA polymerase x RT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Tenofovir Disoproxil Fumarate (query alias: tenofovir disoproxil) |
|---|---|
| Modality / target | Small molecule drug; DNA polymerase x RT; DNA polymerase inhibitors, RT inhibitors |
| Highest global status | Approved |
| Originator | Gilead Sciences, Inc. |
| Active developers | Gilead Sciences Ireland UC, Gilead Sciences Pty Ltd., GSK Plc |
The MCP disease footprint includes Virus Diseases, Hepatitis B, Hepatitis B, Chronic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07658976 | Phase 3 | Not yet recruiting | 400 | To determine the efficacy of the 3P mHealth package on PrEP uptake among participants |
| NCT07553767 | Early Phase 1 | Not yet recruiting | 156 | Concentration of Hepatitis B Surface Antigen (Hepatitis B Surface Antigen, HBsAg) |
| NCT07558967 | Phase 1 | Completed | 47 | Cmax |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants With Chronic Hepatitis B Infection (PREVAIL)
Phase 1/2; n=33; evaluation: not stated. Reported fields: -; -; -
Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
Phase 4; n=153; evaluation: Positive. Reported fields: HBV DNA = 98.5 IU/mL ; HBV DNA = 100.0 IU/mL
Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Phase 3; n=1298; evaluation: Positive. Reported fields: eGFR/BMD = remained stable in patients receiving double-blind/OL TAF, with only small declines at year 8. Decreases in BMD observed during double-blind TDF improved after switching to OL TAF ; eGFR/BMD = remained stable in patients receiving double-blind/OL TAF, with only small declines at year 8. Decreases in BMD observed during double-blind TDF improved after switching to OL TAF ; eGFR/BMD = remained stable in patients receiving double-blind/OL TAF, with only small declines at year 8. Decreases in BMD observed during double-blind TDF improved after switching to OL TAF
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Tenofovir Disoproxil Fumarate addresses Virus Diseases, Hepatitis B, Hepatitis B, Chronic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-06-29 | Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection | Approved | Financial terms not disclosed |
| 2018-11-29 | JT Terminates Agreements with Gilead Sciences on Exclusive Rights to Develop, Commercialize and Market of Six Anti-HIV Drugs in Japan | Approved | Financial terms not disclosed |
| 2016-11-22 | Reeling From GlobeImmune Hepatitis B Termination with Gilead Sciences, Gilead Faces Merck & Co., GlaxoSmithKline Competition | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Antibody-drug conjugates for treating infections of human immunodeficiency virus (HIV)”. The milestone feed surfaced a patent-application signal described as “Methods for treating monkeypox infections”. The milestone feed surfaced a patent-application signal described as “Methods and compositions for the treatment of viral diseases”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
